Breaking News
June 24, 2018 - Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant
June 24, 2018 - Researchers discover new type of cell that hinders formation of fat cells
June 24, 2018 - Scientists develop unique program to predict a form of Parkinson’s disease
June 24, 2018 - Adult Obesity Prevalence Varies With Level of Urbanization
June 24, 2018 - Picking an exercise boot camp
June 24, 2018 - Researchers outline a connection between subplate neurons and brain disorders
June 24, 2018 - Four cups of coffee a day shown to protect heart muscle
June 24, 2018 - ‘Antifreeze’ molecules may hold key to better treatments for brain injuries
June 24, 2018 - Opening onsite health clinics for workers can cut health care costs
June 24, 2018 - Glooko to demonstrate new version of diabetes management mobile application at ADA meeting
June 24, 2018 - Florida Teen First Human Case of Another Mosquito-Borne Virus
June 24, 2018 - Blood type O patients may have higher risk of death from severe trauma
June 24, 2018 - New studies on molecular and cellular proteomics
June 24, 2018 - Algorithm predicts dangerous low blood pressure during surgery
June 24, 2018 - Herpes may play role in pathogenesis of Alzheimer’s
June 24, 2018 - Inaccurate measurement of sodium intake may account for paradoxical results, study suggests
June 24, 2018 - Aquinnah Pharmaceuticals wins NINDS grant to advance novel therapies for ALS
June 24, 2018 - Study upends conventional view of opioid mechanism of action
June 24, 2018 - Floppy eyelids may be sign of sleep apnea, study finds
June 23, 2018 - Researchers highlight new nurse training model to address shortage of primary care
June 23, 2018 - New Olympus cellSens 2.1 speeds up image analysis
June 23, 2018 - Attitudes Among Obese Are Not Aligned With Healthy Living
June 23, 2018 - Early birds less prone to depression
June 23, 2018 - Scientists use novel approach to uncover how brain networks interact to make word-choice decisions
June 23, 2018 - Researchers discover shared genetic basis for psychiatric disorders
June 23, 2018 - Study shows fat cells increase in size and number upon exposure to fracking chemicals
June 23, 2018 - Water-limited landscapes can facilitate disease transmission
June 23, 2018 - Exercise May Ease Inflammation Tied to Obesity
June 23, 2018 - Is it their own fault?! How people judge the exclusion of others
June 23, 2018 - Researchers use advanced technology to identify proteomes of Th17 and iTreg cells
June 23, 2018 - Researchers develop low-cost plastic sensors to monitor wide range of health conditions
June 23, 2018 - Lipid-scrambling DNA enzyme outperforms naturally occurring counterpart, say researchers
June 23, 2018 - Apps for children should emphasize parent and child choice, researchers say
June 23, 2018 - Teenage girls report higher degree of daytime sleepiness than boys
June 23, 2018 - Protein Data Bank at Rutgers impacts research, education and drug discovery
June 23, 2018 - Study unravels new piece of information in the Huntington’s disease puzzle
June 23, 2018 - Scientists develop new device to test cancer drug combinations quickly and cheaply
June 23, 2018 - Neural Analytics wins CE Mark for NeuralBot System
June 23, 2018 - Infant omega-3 supplementation tied to decreased waist size
June 23, 2018 - Massive analysis of genomes reveals insights into genetic overlap among psychiatric diseases
June 23, 2018 - New therapeutic approach may delay neurodegeneration in rare genetic disease
June 23, 2018 - Broken shuttle protein may hinder learning in patients with brain disorders
June 23, 2018 - Study finds increase in daily cannabis use among American adults
June 23, 2018 - Researchers create electronic skin that brings back real sense of touch to prosthetic limbs
June 23, 2018 - FIRS: Guidance Offered for Protecting Youth From E-Cigarettes
June 23, 2018 - Scientists unravel molecular mechanisms of Parkinson’s disease
June 23, 2018 - When the Heart Stops, Drugs Often to Blame
June 23, 2018 - Scientists show that a key Parkinson’s biomarker can be identified in the retina
June 23, 2018 - Study finds factors underlying current rise in radicalization among European youth
June 23, 2018 - New study finds higher heart disease risk in bisexual men
June 23, 2018 - Coconut oil diet increases vitality, lifespan of fruit flies with peroxisomal disorder
June 23, 2018 - Jumping genes or transposons and their role in the genetic code
June 23, 2018 - The Current issue of “The view from here” is concerned with Therapeutics
June 23, 2018 - Abnormal lipid metabolism in fat cells predicts future weight gain and diabetes in women
June 23, 2018 - Alcohol problems linked to sex without condom use among black gay men
June 23, 2018 - DNA patterns in circulating blood cells can help identify spastic cerebral palsy
June 23, 2018 - Unsubstantiated health claims widespread within weight loss industry
June 23, 2018 - FDA grants marketing authorization for use of two catheter-based devices in hemodialysis patients
June 23, 2018 - An ingrown toenail not the same as a bypass
June 23, 2018 - Study suggests proteinuria lowering as important target in managing pediatric CKD
June 23, 2018 - Dynamic model helps make predictions about gut microbiome
June 23, 2018 - Research consortium wins £2.9 million to help tackle antibacterial resistance in Thailand
June 23, 2018 - Schizophrenia patients account for over 1 in 10 suicide deaths, study shows
June 23, 2018 - Overdose risk increases five-fold with concurrent opioid and benzodiazepine use
June 23, 2018 - FDA Alert: Kratom (mitragyna speciosa) powder products by Gaia Ethnobotanical: Recall
June 23, 2018 - Study highlights inadequate effort of health care insurers to combat opioid epidemic
June 23, 2018 - CDC chief asks for, and gets, cut to his record $375K pay
June 22, 2018 - Novel cellular pathway may clarify how arterial inflammation develops into atherosclerosis
June 22, 2018 - Pioneering exercise program improves physical, mental health of elderly people living in care homes
June 22, 2018 - Rutgers Cancer Institute educates childhood cancer survivors about late effects of treatment
June 22, 2018 - Study tests accuracy of device designed to detect heart dysfunction in childhood cancer survivors
June 22, 2018 - Study links annual haze with increased hospitalizations for respiratory problems
June 22, 2018 - Robotic surgery appears to be as effective as open surgery in treating bladder cancer
June 22, 2018 - Many Drugs Made Available Via FDA Expanded Access Programs
June 22, 2018 - Normal eye dominance is not necessary for restoring visual acuity in amblyopia
June 22, 2018 - Parent-Child Interaction Therapy can reduce depression rates in children
June 22, 2018 - Study provides insights into how components of different cells in the brain are altered
June 22, 2018 - Research does not confirm antidiabetic action of natural fatty acid derivatives
June 22, 2018 - Oxidative stress can be used against tumors to treat cancer
June 22, 2018 - Simple, cost-effective test may help improve early diagnosis of mild cognitive impairment
Combo Tx Active in Locally Advanced Pancreatic Ca

Combo Tx Active in Locally Advanced Pancreatic Ca

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

SAN FRANCISCO — Time to treatment failure in newly diagnosed locally advanced pancreatic cancer exceeded historical standards in patients who received induction therapy with nab-paclitaxel (Abraxane) and gemcitabine, a preliminary trial showed.

The median time to treatment failure (TTF) was 8.8 months compared with the historical duration of 6.6 months. Median progression-free survival approached 1 year, and more than 70% of patients remained alive at 1 year, according to Pascal Hammel, MD, of Hopital Beaujon in Clichy, France, and colleagues.

The findings add to the combination’s activity in pancreatic cancer, following phase III results showing improved survival in association with a significant reduction in tumor burden among patients with metastatic pancreatic cancer, they reported here at the Gastrointestinal Cancers Symposium (GICS).

“The combination of nab-paclitaxel and gemcitabine has promising antitumor activity,” Hammel concluded. “Induction therapy was tolerable and consistent with the known safety profile of the drugs. Quality of life was maintained in most patients. The combination allowed conversion to tumor resection in 16 of 102 patients.”

The single-arm nature of the trial complicated interpretation of the results, said GICS invited discussant Brian M. Wolpin, MD, of Dana-Farber Cancer Institute in Boston. Clinicians can use the results as an aid to patient counseling, and the trial provided data useful for the design and interpretation of future studies.

“These results are unlikely to change clinical practice,” said Wolpin. “Many patients with locally advanced pancreatic cancer already receive multiagent chemotherapy. The study was not designed to definitively demonstrate improvement in patient outcomes. The optimal treatment approach for locally advanced pancreatic cancer remains unclear.”

The rationale for the trial, known as LAPACT, came from recognition that 30% of patients with pancreatic cancer have unresectable locally advanced tumors at diagnosis. Induction chemotherapy is standard for patients in this clinically setting, Hammel noted.

The previously reported success of the combination in patients with metastatic pancreatic cancer suggested potential efficacy of nab-paclitaxel and gemcitabine for locally advanced disease. The National Comprehensive Cancer Network previously gave a qualified recommendation to the combination for locally advanced disease on the basis of the trial in the metastatic setting, Hammel stated.

Investigators in the LAPACT trial enrolled 107 patients with newly diagnosed, locally advanced pancreatic cancer. The patients received a maximum of six cycles of induction therapy with nab-paclitaxel and gemcitabine. Investigators then had the option to continue the combination, treat patients with chemoradiation, or proceed to surgical resection.

All but one patient started induction therapy, and 61 of them completed the planned therapy. Subsequently, 12 patients continued the combination, 17 had chemoradiation, and 16 underwent surgical resection. The remaining 16 did not receive investigator’s choice of treatment after induction.

The protocol-specified standard for time to treatment failure was 6.6 weeks. After follow-up for as long as 24 months, the cohort had a median TTF of 8.8 weeks (90% CI 6.67-9.82).

The induction therapy led to partial response in 35 (32.7%) of 107 patients in the intention-to-treat population. An additional 62 (57.9%) patients had stable disease of at least 16 weeks. The disease control rate (response plus stable disease) was 77.6% if stable disease were defined as ≥16 weeks and 65.4% if defined as ≥24 weeks. Hammel said 38.2% of patients had a reduction in tumor size >30%, most patients had some tumor reduction during induction therapy.

In patients with paired measurements of serum CA19-9, 75.3% had at least a 50% reduction in the cancer antigen, and 56.2% had at least a 70% reduction.

Of the 16 patients who underwent surgical resection after induction therapy, seven had clear surgical margins (R0) and the remaining nine had microscopic residual disease (R1).

The study was supported by Celgene.

Hammel disclosed relevant relationships with Celgene, Shire, Ipsen, and Merck Serono.

2018-01-21T13:30:00-0500

Tagged with:

About author

Related Articles